July 9, 2015 - During an event with Massachusetts Gov. Charlie Baker in June, Abiomed announced a major expansion of its U.S. headquarters in Danvers, Massachusetts, and the creation of approximately 100 new, local jobs.
Abiomed will lease an additional 85,000 square feet of space in a building adjacent to its current U.S. headquarters in Danvers. The added space will be dedicated to manufacturing and research.
The company currently has more than 600 employees, nearly half of which work in Massachusetts. Over the past two years, Abiomed has already added 150 jobs in the Commonwealth.
Duane Pinto, M.D., a cardiologist and director of the cardiac intensive care unit at Beth Israel Deaconess Medical Center, also attended the event at Abiomed's Danvers headquarters.
Plans for Abiomed's U.S. expansion follow two recent U.S. Food and Drug (FDA) approvals of its heart pump devices. Most recently, in March, Abiomed received a FDA Pre-Market Approval (PMA) for the Impella 2.5 heart pump to be using during elective and urgent high-risk percutaneous coronary intervention (PCI) procedures.
As many as 100,000 U.S. cardiac patients are turned down for heart surgery each year because the risks are too high, and the Impella 2.5 is approved for use to help patients maintain stable heart function and circulation during certain high-risk procedures.
In January, Abiomed's Impella RP (Right Percutaneous) System received FDA approval under a Humanitarian Device Exemption (HDE). The Impella RP is a single access right-sided percutaneous ventricular assist device and is FDA indicated for providing circulatory assistance to pediatric or adult patients who develop acute right heart failure or decompensation for up to 14 days.
For more information: www.abiomed.com
